Annual report pursuant to Section 13 and 15(d)

Note 3 - Supplemental Balance Sheet and Cash Flow Information (Details Textual)

v3.7.0.1
Note 3 - Supplemental Balance Sheet and Cash Flow Information (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2016
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Amortization of Intangible Assets   $ 44,393 $ 29,395  
Other Assets, Noncurrent   44,002 1,922  
Available-for-sale Securities   66,100 31,600  
Payments to Acquire Available-for-sale Securities   3,069
Astute Medical, Inc. [Member]        
Payments to Acquire Investments $ 40,000      
Developed Technology Rights [Member] | Cost of Sales [Member]        
Amortization of Intangible Assets   23,100 11,100 9,500
Trade Names, Customer Relationships, Non-Compete Agreements, and Patents [Member] | Selling, General and Administrative Expenses [Member]        
Amortization of Intangible Assets   $ 21,300 18,300 $ 16,700
ChemoCentryx, Inc (CCXI) [Member]        
Share Price   $ 9.36    
ChemoCentryx, Inc (CCXI) [Member]        
Available-for-sale, Amortized Cost Basis, Price Per Share   $ 4.73    
Available-for-sale Securities, Gross Unrealized Gain (Loss)   $ 31,000    
Available-for-sale Equity Securities, Amortized Cost Basis   29,500 $ 29,500  
Available-for-sale Equity Securities, Gross Unrealized Gain   30,100    
Certificates Of Deposit [Member] | CHINA        
Payments to Acquire Available-for-sale Securities   1,400    
Advanced Cell Diagnostics (ACD) [Member] | Available-for-sale Securities [Member]        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities   $ 2,100